Featured Research

from universities, journals, and other organizations

Toward An Ultra-sensitive Blood Test For Breast Cancer

Date:
August 29, 2006
Source:
American Chemical Society
Summary:
An international research group is reporting development and early clinical testing of an ultra-sensitive blood test for breast cancer. Their new immunoassay was 200-1,000 times more sensitive than existing tests, according to a report scheduled for the Aug. 4 issue of the ACS' Journal of Proteome Research.

An international research group is reporting development and early clinical testing of an ultra-sensitive blood test for breast cancer.

Their new immunoassay was 200-1,000 times more sensitive than existing tests, according to a report scheduled for the Aug. 4 issue of the ACS' Journal of Proteome Research.

Jasminka Godovac-Zimmermann, of University College London, headed the group, which included scientists from the University of Pennsylvania, the University of Pittsburgh and BioTraces, Inc. in Herndon, Va.

Tests on 250 breast cancer patients and 95 controls showed that the test had sensitivity and specificity of about 95 percent -- an important consideration in determining the false-positive and false-negative results of a diagnostic test.

Breast cancer originates in so-called epithelial cells, and the researchers cited pilot studies suggesting that the test could work for epithelial cancers. Those include prostate cancer, ovarian cancer and melanoma.

In their report, the researchers cite a need for a more effective way of screening for breast cancer -- especially in younger women for whom mammography is less sensitive.

"Better blood-based testing may aid in early diagnosis, may reduce the need for open biopsy and could provide new modalities for monitoring of therapy," they write.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Toward An Ultra-sensitive Blood Test For Breast Cancer." ScienceDaily. ScienceDaily, 29 August 2006. <www.sciencedaily.com/releases/2006/08/060826215007.htm>.
American Chemical Society. (2006, August 29). Toward An Ultra-sensitive Blood Test For Breast Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/08/060826215007.htm
American Chemical Society. "Toward An Ultra-sensitive Blood Test For Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/08/060826215007.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins